[HTML][HTML] New perspectives on the immunopathogenesis and treatment of uveitis associated with Vogt-Koyanagi-Harada disease
AM Abu El-Asrar, J Van Damme, S Struyf… - Frontiers in …, 2021 - frontiersin.org
Uveitis associated with Vogt-Koyanagi-Harada (VKH) disease is a bilateral, chronic,
granulomatous autoimmune disease associated with vitiligo, poliosis, alopecia, and …
granulomatous autoimmune disease associated with vitiligo, poliosis, alopecia, and …
Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?
A Cipponi, G Wieers, N Van Baren… - Cancer Immunology …, 2011 - Springer
Tumor-infiltrating T lymphocytes (TILs) are observed in a number of human primary or
metastatic tumors. Recently, gene expression profiling experiments suggested that the …
metastatic tumors. Recently, gene expression profiling experiments suggested that the …
A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice
N Demotte, G Wieërs, P Van Der Smissen, M Moser… - Cancer research, 2010 - AACR
Human CD8+ tumor-infiltrating T lymphocytes (TIL), in contrast with CD8+ blood cells, show
impaired IFN-γ secretion on ex vivo restimulation. We have attributed the impaired IFN-γ …
impaired IFN-γ secretion on ex vivo restimulation. We have attributed the impaired IFN-γ …
A short treatment with galactomannan GM-CT-01 corrects the functions of freshly isolated human tumor–infiltrating lymphocytes
N Demotte, R Bigirimana, G Wieërs, V Stroobant… - Clinical Cancer …, 2014 - AACR
Purpose: Several galectins are released by tumor cells and macrophages and accumulate
in the tumor microenvironment. Galectin-1 and-3 were found to bind to glycosylated …
in the tumor microenvironment. Galectin-1 and-3 were found to bind to glycosylated …
[HTML][HTML] Th lymphocyte subsets in patients with Vogt-Koyanagi-Harada disease
L Liang, XY Peng, H Wang - International journal of ophthalmology, 2019 - ncbi.nlm.nih.gov
AIM To assess helper T (Th) lymphocyte subset balance in patients with Vogt-Koyanagi-
Harada (VKH) disease. METHODS Sixty-eight active VKH patients and seventy-two inactive …
Harada (VKH) disease. METHODS Sixty-eight active VKH patients and seventy-two inactive …
Hearing status in patients with vitiligo
H Rahimi, N Mozafari, S Bastaninejad… - Clinical, Cosmetic …, 2019 - Taylor & Francis
Background: Vitiligo is an acquired disorder characterized by depigmented macules and
patches that result from a progressive loss of functional melanocytes. During …
patches that result from a progressive loss of functional melanocytes. During …
Vogt-Koyanagi-Harada disease
A Joye, E Suhler - Current opinion in ophthalmology, 2021 - journals.lww.com
Vogt-Koyanagi-Harada disease : Current Opinion in Ophthalmology Vogt-Koyanagi-Harada
disease : Current Opinion in Ophthalmology Log in or Register Subscribe to journalSubscribe …
disease : Current Opinion in Ophthalmology Log in or Register Subscribe to journalSubscribe …
[HTML][HTML] A case presentation of an IgA nephropathy patient with Vogt-Koyanagi-Harada syndrome
Q Zhang, X Fan, M Tian, H Han - BMC nephrology, 2020 - Springer
Abstract Background Vogt-Koyanagi-Harada syndrome is a rare disease characterized by
skin and eyelash bleaching, chronic granulomatous iridocyclitis and exudative retinal …
skin and eyelash bleaching, chronic granulomatous iridocyclitis and exudative retinal …
Hearing restoration and the stria vascularis: evidence for the role of the immune system in hearing restoration
NL Samaha, MM Almasri, JD Johns… - Current opinion in …, 2021 - journals.lww.com
This review highlights the current literature regarding the pathogenesis of immune-mediated
hearing loss. The role of cochlear structures in human temporal bones from patients with …
hearing loss. The role of cochlear structures in human temporal bones from patients with …
[HTML][HTML] Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccines
G Wieërs, N Demotte, D Godelaine, P Van der Bruggen - Cancers, 2011 - mdpi.com
Human tumors are usually not spontaneously eliminated by the immune system and
therapeutic vaccination of cancer patients with defined antigens is followed by tumor …
therapeutic vaccination of cancer patients with defined antigens is followed by tumor …